4 syllables: Ri, tux, i, mab. Stress on tux.
rit-UHK-sim-ab
/ɹɪˈtʌksɪmæb/
Rituximab is pronounced rit-UHK-sim-ab (/ɹɪˈtʌksɪmæb/). It has four syllables (Ri-tux-i-mab), with the stress on "tux". Rituximab is a monoclonal antibody used to treat certain cancers and autoimmune diseases. It is a pharmaceutical agent administered via IV, designed to target CD20 on B-cells. In medical contexts, it’s discussed as a biologic therapy with specific dosing regimens and monitoring requirements.
nounRituximab is a monoclonal antibody used to treat certain cancers and autoimmune diseases. It is a pharmaceutical agent administered via IV, designed to target CD20 on B-cells. In medical contexts, it’s discussed as a biologic therapy with specific dosing regimens and monitoring requirements.
How to Pronounce Rituximab
"The patient received Rituximab as part of the lymphoma treatment protocol."
"Researchers studied the efficacy of Rituximab in autoimmune vasculitis."
"Patients must be screened for infusion reactions before Rituximab administration."
Rituximab is pronounced rii-TOOK-si-mab, with primary stress on the second syllable 'TOOK' (IPA US: riːˈtʌk.sɪ.mæb). Start with a long 'ee' sound in 'ri', then the cluster 'tux' sounds like 'toox' but with a crisp 't' and schwa-like 's' before 'i'. The final 'mab' rhymes with 'cab' and 'dab'. Visualize it as three beats: ri-TOOK-si-mab. In IPA you can think /riːˈtʊk.sɪ.mæb/. In phonemic terms: /riːˈtʌkˌsiː mæb/ depending on dialect; aim for /riːˈtʊk.si.mæb/ for US general. Listening to medical speakers will help you align your articulation.
Common mistakes include compressing the middle syllable into a short 'tux' with reduced vowel, e.g., ri-TUX-i-mab, and misplacing stress on the third syllable or flattening the ending as 'mabb'. Another frequent error is pronouncing it with a hard 'a' as in 'cab' twice (caB) instead of a short 'a' as in 'cat'. Correction: keep the second syllable stressed and use the clear 'i' as a short vowel after 's' (si) and finish with a clean 'mab' (mӕb). Practice the three-segment rhythm: ri-TOOK-si-mab, with a slight delay before the final syllable.
Across accents, the key differences are vowel quality in the stressed syllable and the rhoticity of the 'r'. In US and Canadian English, /riːˈtʊk.si.mæb/ or /riːˈtʊk.sɪ.mæb/ with rhotic r and a tense 'u' in 'took'. UK speakers often maintain similar rhotics, but some non-rhotic tendencies may soften the initial 'r' slightly and produce a shorter 'u' vowel, more like /riːˈtʌk.sɪ.mæb/. Australian English tends to be rhotic with slightly broader vowels and a flatter final syllable, e.g., /riːˈtʌk.sɪˈmæb/ in rapid speech. Listening to targeted medical pronunciations helps calibrate these variants.
It's difficult because of the long 'ee' and short 'i' vowels in quick succession, the consonant cluster 'tux' with a crisp 't,' and the final 'mab' that can be read as 'mabe' by some. The combination of rare pharma-based root sounds and the -mab suffix (monoclonal antibody) introduces unfamiliar cadence for non-medical speakers. Take your time on the second syllable, and practice by chunking the word into three parts: ri- (roll the 'r' lightly), tux (short 'u' like 'took' but faster), imab (short 'i' followed by 'mab').
A unique detail is the 'tux' portion where the 'tu' sounds like 'too' in US pronunciations, with a clipped 'k' following swiftly. Do not elide the 'si' in the penultimate syllable; keep it as a clear 'si' rather than a schwa. This keeps a stable three-syllable rhythm that clinicians expect in fast-spoken rounds or orders. Emphasize second syllable while keeping a light, neutral tone on the final 'mab' to avoid trailing off.
🗣️ Voice search tip: These questions are optimized for voice search. Try asking your voice assistant any of these questions about "Rituximab"!
Rituximab derives from the target and mechanism components within its name. The first element, 'Ritu-,' is a conventional stem that does not carry standalone lexical meaning in medicine but is often seen across biologics of similar naming patterns. The middle segment 'xu-' is a phonotactic sequence common in pharmaceutical nomenclature to convey a unique molecular identity, while the final '-mab' is the standard suffix for monoclonal antibodies, borrowed from 'antibody' and Latin -mab, signalling biologic origin. The term likely coalesced in the late 1990s–early 2000s as monoclonal antibody therapies expanded beyond conventional chemotherapies. Rituximab was developed to target CD20 on B cells, with the American FDA approving it in 1997 for certain lymphomas, and subsequent indications broadened to autoimmune diseases. The word thus sits at the intersection of clinical naming conventions (mab suffix), biologic therapies, and disease-target specificity, with its pronunciation becoming standardized in medical literature and clinical practice worldwide. First known uses appear in pharmacology product labels, peer-reviewed trials, and prescribing information during the late 1990s and early 2000s, cementing Rituximab as a cornerstone therapy in hematology and rheumatology. Over time, the word has maintained its two-stress pattern and clear syllabic segmentation, aiding clinicians and patients in accurate spoken communication across multilingual settings.
💡 Etymology tip: Understanding word origins can help you remember pronunciation patterns and recognize related words in the same language family.
Help others use "Rituximab" correctly by contributing grammar tips, common mistakes, and context guidance.
💡 These words have similar meanings to "Rituximab" and can often be used interchangeably.
🔄 These words have opposite meanings to "Rituximab" and show contrast in usage.
📚 Vocabulary tip: Learning synonyms and antonyms helps you understand nuanced differences in meaning and improves your word choice in speaking and writing.
Words that rhyme with "Rituximab"
-nab sounds
Practice with these rhyming pairs to improve your pronunciation consistency:
🎵 Rhyme tip: Practicing with rhyming words helps you master similar sound patterns and improves your overall pronunciation accuracy.
